Patents by Inventor Johnathan M. Lancaster
Johnathan M. Lancaster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10982284Abstract: Disclosed are compositions and methods for assessing the apoptosis and survival BAD phosphorylation pathway (BAD pathway); and/or (2) the cell cycle role of APC in cell cycle regulation pathway (APC pathway); and/or (3) the transcription CREB pathway (CREB pathway) and for using these pathways to assess, treat, monitor, prognose, diagnose, etc. subjects with cancer. Also disclosed are compositions and methods for identifying molecular pathways that are common to one or more chemotherapeutic agents for the treatment of an oncological disorder, for screening for compounds or agents that can be used to treat ovarian cancer, and for selecting for compounds or agents that can enhance the cytotoxic response of cisplatin, carboplatin, and/or paclitaxel against a cancer cell, such as an ovarian cancer cell or cell line.Type: GrantFiled: March 5, 2012Date of Patent: April 20, 2021Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Johnathan M. Lancaster, Yin Xiong
-
Publication number: 20180238892Abstract: The present invention relates to the BAD pathway's influence on development, progression, chemo-sensitivity, and overall survival for multiple human cancers and its potential as a therapeutic target to increase chemo-sensitivity. BAD pathway expression was associated with the development and/or progression of breast, colon, and endometrial cancers, relapse-free survival from breast cancer, and overall survival from ovarian, colon, and brain cancers. Expression was also associated with in vitro sensitivity to a range of cytotoxic agents. pBAD levels were higher in cancer versus immortalized normal cells and chemo-resistant versus—sensitive cancer cells and associated with increased cell proliferation.Type: ApplicationFiled: April 24, 2018Publication date: August 23, 2018Inventors: Johnathan M. Lancaster, Douglas C. Marchion, Yin Xiong
-
Patent number: 9983209Abstract: The present invention relates to the BAD pathway's influence on development, progression, chemo-sensitivity, and overall survival for multiple human cancers and its potential as a therapeutic target to increase chemo-sensitivity. BAD pathway expression was associated with the development and/or progression of breast, colon, and endometrial cancers, relapse-free survival from breast cancer, and overall survival from ovarian, colon, and brain cancers. Expression was also associated with in vitro sensitivity to a range of cytotoxic agents. pBAD levels were higher in cancer versus immortalized normal cells and chemo-resistant versus—sensitive cancer cells and associated with increased cell proliferation.Type: GrantFiled: November 10, 2014Date of Patent: May 29, 2018Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Johnathan M. Lancaster, Douglas C. Marchion, Yin Xiong
-
Patent number: 9809858Abstract: Biomarkers, methods, assays, and kits are provided for determining the prognosis of and treating a patient with ovarian cancer. Also disclosed are biomarkers, methods, assays, and kits for predicting the sensitivity of ovarian cancer cells to chemotherapy.Type: GrantFiled: April 5, 2013Date of Patent: November 7, 2017Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Johnathan M. Lancaster, Douglas C. Marchion, Yin Xiong
-
Patent number: 9442116Abstract: Disclosed is a method of predicting clinical tumor outcome by providing gene expression from a tumor sample. The method utilizes a novel genetic screen to identify genes that contribute to chemotherapeutic responsiveness, using formalin fixed paraffin embedded clinical samples of epithelial cancer, specifically serous ovarian cancer. The method is useful in predicting tumor responsiveness to chemotherapeutics, including alkylating agents, cisplatin, antimetabolites, plant alkaloids, and antitumor antibiotics. A microarray screen showed formalin fixed paraffin embedded samples can identify genes related to chemotherapeutic response with 86% efficiency.Type: GrantFiled: April 23, 2010Date of Patent: September 13, 2016Assignee: University of South FloridaInventor: Johnathan M. Lancaster
-
Publication number: 20150302140Abstract: Disclosed is an in silico method to identify molecular signaling pathways that influence cancer development as well as therapeutic compounds with activity against them.Type: ApplicationFiled: November 4, 2013Publication date: October 22, 2015Applicant: H. LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventors: Johnathan M. Lancaster, Yin Xiong
-
Publication number: 20150154368Abstract: Methods and apparatuses using molecular fingerprints to provide targeted therapeutic strategies are disclosed herein. The molecular fingerprints can be maintained and dynamically updated based on newly discovered and relevant information to improve individualized care.Type: ApplicationFiled: July 25, 2013Publication date: June 4, 2015Inventors: Johnathan M. Lancaster, James J. Mulé
-
Publication number: 20150140124Abstract: The present invention relates to the BAD pathway's influence on development, progression, chemo-sensitivity, and overall survival for multiple human cancers and its potential as a therapeutic target to increase chemo-sensitivity. BAD pathway expression was associated with the development and/or progression of breast, colon, and endometrial cancers, relapse-free survival from breast cancer, and overall survival from ovarian, colon, and brain cancers. Expression was also associated with in vitro sensitivity to a range of cytotoxic agents. pBAD levels were higher in cancer versus immortalized normal cells and chemo-resistant versus—sensitive cancer cells and associated with increased cell proliferation.Type: ApplicationFiled: November 10, 2014Publication date: May 21, 2015Inventors: Johnathan M. Lancaster, Douglas C. Marchion, Yin Xiong
-
Publication number: 20150080249Abstract: Biomarkers, methods, assays, and kits are provided for determining the prognosis of and treating a patient with ovarian cancer. Also disclosed are biomarkers, methods, assays, and kits for predicting the sensitivity of ovarian cancer cells to chemotherapy.Type: ApplicationFiled: April 5, 2013Publication date: March 19, 2015Inventors: Johnathan M. Lancaster, Douglas C. Marchion, Yin Xiong
-
Publication number: 20130344168Abstract: Disclosed are compositions and methods for assessing the apoptosis and survival BAD phosphorylation pathway (BAD pathway); and/or (2) the cell cycle role of APC in cell cycle regulation pathway (APC pathway); and/or (3) the transcription CREB pathway (CREB pathway) and for using these pathways to assess, treat, monitor, prognose, diagnose, etc. subjects with cancer. Also disclosed are compositions and methods for identifying molecular pathways that are common to one or more chemotherapeutic agents for the treatment of an oncological disorder, for screening for compounds or agents that can be used to treat ovarian cancer, and for selecting for compounds or agents that can enhance the cytotoxic response of cisplatin, carboplatin, and/or paclitaxel against a cancer cell, such as an ovarian cancer cell or cell line.Type: ApplicationFiled: March 5, 2012Publication date: December 26, 2013Applicant: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Johnathan M. Lancaster, Yin Xiong
-
Patent number: 8257919Abstract: A method predicting of cancer chemoresponse of the population of cancer cells to the one or more chemotherapeutic agents. Our ability to treat patients with advanced stage and recurrent endometrial cancer is hampered by an incomplete understanding of the molecular basis of disease development and response to therapy. A novel class of gene products called microRNA (miRNA) has recently been implicated in the etiology of several different human cancers. Altered levels of expression of specific miRNAs may contribute to cancer development in a variety of cancers such as endometrial cancer and may also influence response to cytotoxic chemotherapy or other cancer treatments. Evidence is provided that differential expression of miRNAs contributes to endometrial carcinogenesis and further associates with sensitivity of endometrial cancer cells to various chemotherapeutic agents including cisplatin and doxorubicin chemotherapy.Type: GrantFiled: August 3, 2009Date of Patent: September 4, 2012Assignee: University of South FloridaInventor: Johnathan M. Lancaster
-
Publication number: 20110166095Abstract: The phosphorylation status of the BAD protein is a determinant of ovarian cancer cell responsiveness to platinum chemotherapy. Indirect manipulation of BAD phosphorylation status influences cisplatin sensitivity. BAD phosphorylation represents a biomarker that predicts platinum sensitivity and is a therapeutic target to increase platinum sensitivity. The methods employ phospho-specific antibody against a particular amino acid residue or site. Phospho-specific protein characterization methods include immunohistochemical (IHC), flow cytometric, immunofluorescent, capture-and-detection, or reversed phase assay.Type: ApplicationFiled: December 22, 2010Publication date: July 7, 2011Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South FloridaInventors: Johnathan M. Lancaster, Douglas C. Marchion, Dung-Tsa Chen
-
Publication number: 20100305058Abstract: The invention provides for compositions and methods for predicting an individual's responsitivity to cancer treatments and methods of treating cancer. In certain embodiments, the invention provides compositions and methods for predicting an individual's responsitivity to chemotherapeutics, including platinum-based chemotherapeutics, to treat cancers such as ovarian cancer. Furthermore, the invention provides for compositions and methods for predicting an individual's responsivity to salvage therapeutic agents. By predicting if an individual will or will not respond to platinum-based chemotherapeutics, a physician can reduce side effects and toxicity by administering a particular additional salvage therapeutic agent. This type of personalized medical treatment for ovarian cancer allows for more efficient treatment of individuals suffering from ovarian cancer.Type: ApplicationFiled: April 16, 2010Publication date: December 2, 2010Applicants: Duke University, University of South FloridaInventors: Johnathan M. Lancaster, Joseph R. Nevins
-
Publication number: 20100292087Abstract: Disclosed is a method of predicting clinical tumor outcome by providing gene expression from a tumor sample. The method utilizes a novel genetic screen to identify genes that contribute to chemotherapeutic responsiveness, using formalin fixed paraffin embedded clinical samples of epithelial cancer, specifically serous ovarian cancer. The method is useful in predicting tumor responsiveness to chemotherapeutics, including alkylating agents, cisplatin, antimetabolites, plant alkaloids, and antitumor antibiotics. A microarray screen showed formalin fixed paraffin embedded samples can identify genes related to chemotherapeutic response with 86% efficiency.Type: ApplicationFiled: April 23, 2010Publication date: November 18, 2010Applicant: UNIVERSITY OF SOUTH FLORIDAInventor: Johnathan M. Lancaster
-
Publication number: 20100279957Abstract: Provided herein are methods for predicting the responsiveness of a cancer to a chemotherapeutic agent using gene expression profiles. In particular, methods for predicting the responsiveness to 5-fluorouracil, adriamycin, cytotoxan, docetaxol, etoposide, taxol, topotecan, PB kinase inhibitors and Src inhibitors are provided. Methods for developing treatment plans for individuals with cancer are also provided. Kits including gene chips and instructions for predicting responsiveness and computer readable media comprising responsivity information are also provided.Type: ApplicationFiled: October 20, 2008Publication date: November 4, 2010Inventors: Anil Potti, Joseph R. Nevins, Johnathan M. Lancaster
-
Publication number: 20090291452Abstract: A method predicting of cancer chemoresponse of the population of cancer cells to the one or more chemotherapeutic agents. Our ability to treat patients with advanced stage and recurrent endometrial cancer is hampered by an incomplete understanding of the molecular basis of disease development and response to therapy. A novel class of gene products called microRNA (miRNA) has recently been implicated in the etiology of several different human cancers. Altered levels of expression of specific miRNAs may contribute to cancer development in a variety of cancers such as endometrial cancer and may also influence response to cytotoxic chemotherapy or other cancer treatments. Evidence is provided that differential expression of miRNAs contributes to endometrial carcinogenesis and further associates with sensitivity of endometrial cancer cells to various chemotherapeutic agents including cisplatin and doxorubicin chemotherapy.Type: ApplicationFiled: August 3, 2009Publication date: November 26, 2009Applicant: UNIVERSITY OF SOUTH FLORIDAInventor: Johnathan M. Lancaster
-
Publication number: 20090186024Abstract: The disclosure relates to identifying deregulated pathways in cancer. In certain embodiments, the methods of the disclosure can be used to evaluate therapeutic agents for the treatment of cancer.Type: ApplicationFiled: May 15, 2006Publication date: July 23, 2009Inventors: Joseph R. Nevins, Andrea H. Bild, Guang Yao, Jeffrey T. Chang, Quanli Wang, Anil Potti, David Harpole, Johnathan M. Lancaster, Andrew Berchuck, John A. Olson, Jeffrey R. Marks, Mike West, Holly Dressman
-
Publication number: 20090105167Abstract: The invention provides for compositions and methods for predicting an individual's responsitivity to cancer treatments and methods of treating cancer. In certain embodiments, the invention provides compositions and methods for predicting an individual's responsitivity to chemotherapeutics, including salvage agents, to treat cancers such as ovarian cancer. The invention also provides reagents, such as DNA microarrays, software and computer systems useful for personalizing cancer treatments, and provides methods of conducting a diagnostic business for personalizing cancer treatments.Type: ApplicationFiled: October 19, 2007Publication date: April 23, 2009Applicant: Duke UniversityInventors: Anil Potti, Joseph R. Nevins, Johnathan M. Lancaster